Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

8.365
+0.0650.78%
Volume:2.13M
Turnover:17.73M
Market Cap:8.80B
PE:-19.35
High:8.510
Open:8.295
Low:8.135
Close:8.300
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.84
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.432
ROE:-28.59%
ROA:-19.64%
PB:3.32
PE(LYR):-19.35
PS:7953.99

Loading ...

Ascletis Pharma Widens H1 2026 Loss to RMB 0.32 Billion as R&D Outlays Double; Cash Pile Rises to RMB 2.31 Billion

Bulletin Express
·
Sep 29

Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial

MT Newswires Live
·
Sep 29

Ascletis Reports 48.9% Placebo-Adjusted PASI Reduction in U.S. Proof-of-Concept Study for First-in-Class Oral IL-17A Inhibitor ASC50

Bulletin Express
·
Sep 29

Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study

Reuters
·
Sep 29

Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States

Stock News
·
Sep 29

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis

THOMSON REUTERS
·
Sep 29

HK Stocks in Focus: Biopharma Sector Surges as 10 Ministries Unveil 15th Five-Year Plan; Analysts See Potential 'Claude Moment' for Industry

Stock News
·
Sep 18

Ascletis Pharma Surges on US Obesity Drug Trial Launch

Deep News
·
Sep 10

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

Reuters
·
Sep 09

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Stock News
·
Sep 08

Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity

THOMSON REUTERS
·
Sep 08

Ascletis Pharma Joins Two Chinese Stock Connect Programs

MT Newswires Live
·
Sep 07

Ascletis to Join Shanghai- and Shenzhen-Hong Kong Stock Connect, Unlocking Mainland Investor Access

Bulletin Express
·
Sep 07

Ascletis Announces Inclusion in the Hong Kong Stock Connect List Under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

THOMSON REUTERS
·
Sep 07

歌礼制药-B股价早盘攀升逾8%,重磅减肥药全球III期试验迎来关键里程碑

Deep News
·
Sep 02

Sweden's Klaria Net Loss Narrows on Lower R&D Expenses

Reuters
·
Sep 01

China's United Laboratories Half-Year Profit Drops 82%

Reuters
·
Aug 31

China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 31

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Stock News
·
Aug 31

Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy

THOMSON REUTERS
·
Aug 31